A method for the manufacture of an α,β-unsaturated ketone, which method comprises oxidizing an alkene having —CH.sub.2— adjacent a carbon-carbon double bond to α,β-unsaturated ketone by passing air or oxygen through a solution of the hydrocarbon containing a catalyst consisting of N-hydroxyphthalimide (NHPI) and cobalt diacetate tetrahydrate at standard temperature and pressure during a period of at least 12 hours.

A method for the manufacture of an α,β-unsaturated ketone, which method comprises oxidizing an alkene having —CH.sub.2— adjacent a carbon-carbon double bond to α,β-unsaturated ketone by passing air or oxygen through a solution of the hydrocarbon containing a catalyst consisting of N-hydroxyphthalimide (NHPI) and cobalt diacetate tetrahydrate at standard temperature and pressure during a period of at least 12 hours.

Disclosed are new polycyclic carbogenic molecules and their methods of synthesis. The new polycyclic carbogenic molecules may be utilized in anti-cancer therapies. In particular, the polycyclic carbogenic molecules may be formulated as pharmaceutical compositions that comprise the small molecules, which compositions may be administered in methods of treating and/or preventing cell proliferative diseases and disorders such as cancer. The new polycyclic carbogenic molecules may be prepared from vinyl- or allyl-substituted cyclohexenone precursors via preparation of a silyl bis-enol ether intermediate.

Disclosed are new polycyclic carbogenic molecules and their methods of synthesis. The new polycyclic carbogenic molecules may be utilized in anti-cancer therapies. In particular, the polycyclic carbogenic molecules may be formulated as pharmaceutical compositions that comprise the small molecules, which compositions may be administered in methods of treating and/or preventing cell proliferative diseases and disorders such as cancer. The new polycyclic carbogenic molecules may be prepared from vinyl- or allyl-substituted cyclohexenone precursors via preparation of a silyl bis-enol ether intermediate.

Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:

##STR00001##

Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:

##STR00001##

Methods of preparing unsaturated compounds or analogs through dehydrogenation of corresponding saturated compounds and/or hydrogenation of aromatic compounds are disclosed.

Methods of preparing unsaturated compounds or analogs through dehydrogenation of corresponding saturated compounds and/or hydrogenation of aromatic compounds are disclosed.

Methods of preparing unsaturated compounds or analogs through dehydrogenation of corresponding saturated compounds and/or hydrogenation of aromatic compounds are disclosed.

Methods of preparing unsaturated compounds or analogs through dehydrogenation of corresponding saturated compounds and/or hydrogenation of aromatic compounds are disclosed.